Related Experiment Video
Updated: Jan 22, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Intracranial Methotrexate-Associated Lymphoproliferative Disorder in Rheumatoid Arthritis
Shizuka Miyaza1, Ryosuke Matsuda2, Mitsutoshi Nakamura2
1Department of Neurosurgery, Higashiosaka City Medical Center, Higashiosaka, Japan.
Background:
Methotrexate (MTX) is widely used as an anchor drug for the treatment of rheumatoid arthritis (RA) because of its ability to control pain and inflammation. However, few studies have shown that long-term MTX use can lead to lymphoproliferative disorders (LPDs) in these patients. Here we describe a rare case of intracranial MTX-associated LPD in a patient with RA.
Case Description:
A 68-year-old woman was admitted to our hospital because of progressive right limb palsy. She was diagnosed with RA 15 years ago and has been receiving MTX therapy for the past 5 years. Magnetic resonance imaging of the head revealed a ring-enhancing lesion in the left parietal lobe. Open biopsy was performed for making a definite diagnosis and planning treatment. Hematoxylin-eosin stain revealed dense proliferation of atypical lymphocytes in the perivascular lesion. Immunohistochemistry results were positive for CD20; this lesion was observed as a strong nuclear signal on in-situ hybridization for the Epstein-Barr virus-encoded RNA. Finally, the patient was diagnosed with MTX-associated LPD. We discontinued MTX administration and initiated steroid therapy for RA. The intracranial lesion reduced in size, and her symptoms resolved after MTX discontinuation; no recurrence has been observed at 3 years after MTX discontinuation.
Conclusions:
Intracranial MTX-associated LPD is extremely rare. Here we describe a particular case and review the literature pertaining to intracranial MTX-associated LPD. More attention should be paid to LPD in a patient receiving immunosuppressive treatment for RA.
Insights
Long-term methotrexate treatment for rheumatoid arthritis can rarely lead to intracranial lymphoproliferative disorders (LPDs). Prompt discontinuation of methotrexate and steroid therapy resolved symptoms in a patient with this rare condition.
Area of Science:
- Neurology
- Rheumatology
- Oncology
Background:
- Methotrexate (MTX) is a primary treatment for rheumatoid arthritis (RA), managing pain and inflammation.
- Long-term MTX use is associated with an increased risk of lymphoproliferative disorders (LPDs).
Observation:
- A 68-year-old woman with a 15-year history of RA and 5 years of MTX therapy presented with progressive right limb palsy.
- Brain MRI revealed a ring-enhancing lesion in the left parietal lobe, confirmed by biopsy as CD20-positive atypical lymphocytes with Epstein-Barr virus (EBV) RNA.
- The patient was diagnosed with an intracranial MTX-associated LPD.
Findings:
- Discontinuation of MTX and initiation of steroid therapy led to significant reduction in the intracranial lesion size.
- The patient's neurological symptoms resolved completely after MTX withdrawal.
- No recurrence of the LPD was observed at a 3-year follow-up.
Implications:
- Intracranial MTX-associated LPD is an exceptionally rare but serious complication of RA treatment.
- Increased vigilance for LPD is crucial in RA patients undergoing immunosuppressive therapy.
- This case highlights the importance of considering iatrogenic causes for neurological deficits in RA patients on long-term MTX.
More Related Videos
09:31Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
06:31Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
Published on: October 6, 2023
Related Concept Videos
Intrinsically Disordered Proteins
Other Disorders of Digestive System
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Panic Disorder